跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MYFEMBREE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MYFEMBREE
Authorized
STANDARD
MYFEMBREE
Sumitomo Pharma Switzerland GmbH
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
af81e0016d876e9b
Company
Sumitomo Pharma Switzerland GmbH
Type
Standard
Approval Details
Approval Id
af81e0016d876e9b
Drug Approval Canada Name
MYFEMBREE
Product Name
MYFEMBREE
Status
Marketed
Status Date
2024-01-29
Original Market Date
2024-01-29
Din
02541742
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:18.04
Atc Original
H01CC54 RELUGOLIX, ESTRADIOL AND NORETHISTERONE
Atc Name
h 01 cc 54
Aig Number
0365021001
Company Name
Sumitomo Pharma Switzerland GmbH
Company Address
Aeschengraben 27, Basel, --, Switzerland, 4051
Company Detail Path
/organization/sumitomo-pharma-switzerland-gmbh
Company Information
Pharmaceutical Company Name
Sumitomo Pharma Switzerland GmbH
Country Name
Switzerland
Province Name
Basel-Stadt
City Name
basel,basel-stadt,country_ch
Address
Aeschengraben 27
Active Ingredients
NORETHINDRONE ACETATE
0.5 MG
ESTRADIOL
1 MG
RELUGOLIX
40 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
af81e0016d876e9b
Type
Standard
Back to Health Canada Approvals